Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Pioneering
personalized medicine
in epigenetics

Oryzon now

1 October 2025

ORYZON strengthens patent portfolio for iadademstat with European grant decision covering combinations with PD1/PD-L1 inhibitors

Read more
25 September 2025

ORYZON to participate in upcoming events in September and October

Read more
22 September 2025

ORYZON to sponsor first Phelan-McDermid syndrome (PMS) burden of illness study

Read more

ORYZON is a public clinical stage biopharmaceutical company developing innovative epigenetic personalized medicines for patients with cancer and CNS disorders

About us
Epigenetics

Epigenetics is a regulatory system that controls gene expression without affecting the makeup of the genes themselves. Regulation of gene transcription and translation are key biological determinants for cellular differentiation and function, and transcriptional imbalances play a significant pathogenic role in a number of human diseases.

More info
Therapeutic programs

ORYZON is a clinical stage biopharmaceutical company that leverages epigenetics to discover and develop innovative personalized therapeutics for patients with cancers and CNS disorders. We are able to identify and validate biomarkers and therapeutic targets through our epigenetic platform and translate them into advanced and personalized therapies.

More info
Latest News
  • 1 October 2025

    ORYZON strengthens patent portfolio for iadademstat with European grant decision covering combinations with PD1/PD-L1 inhibitors

    • Read more about ORYZON strengthens patent portfolio for iadademstat with European grant decision covering combinations with PD1/PD-L1 inhibitors
  • 25 September 2025

    ORYZON to participate in upcoming events in September and October

    • Read more about ORYZON to participate in upcoming events in September and October
  • 22 September 2025

    ORYZON to sponsor first Phelan-McDermid syndrome (PMS) burden of illness study

    • Read more about ORYZON to sponsor first Phelan-McDermid syndrome (PMS) burden of illness study
All News
Upcoming events
  • 7-9 October 2025

    BIOSPAIN 2025

    Fira de Barcelona – Montjuïc

    Barcelona

    Spain

    • More details about BIOSPAIN 2025
  • 7 October 2025

    BME Investor Access Event 2025

    Maison de la Chimie

    Paris

    France

    • More details about BME Investor Access Event 2025
  • 8-9 October 2025

    25th Sachs Annual Biotech in Europe Forum 2025

    Mövenpick Hotel

    Basel

    Switzerland

    • More details about 25th Sachs Annual Biotech in Europe Forum 2025
All Events
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel